# IFSC

> IFSC is a VC fund in Shenzhen backing Biotechnology, Health Care and Medical. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Shenzhen, China
- Total investments: 6
- Last investment: Jul 2026
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.ifsc-gd.com/

IFSC is an innovative venture investment management firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 83% |
| Health Care | 4 | 67% |
| Medical | 3 | 50% |
| Biopharma | 1 | 17% |
| Therapeutics | 1 | 17% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 33% |
| Series A | 1 | 17% |
| Series C | 1 | 17% |
| Series D | 1 | 17% |
| Funding Round | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Beyond Therapeutics | Beyond Therapeutics employs its ExCEED technology to speed the discovery and development of novel medications for unmet therapeutic needs. | $29.6M | Series A | Jul 30, 2026 |  |
| Epigenic Therapeutics | Epigenic Therapeutics is a biotech firm that offers gene editing therapy. | $60M | Series B | Sep 07, 2025 |  |
| Reforgene Medicine | Reforgene Medicine is a biomedical company that uses gene editing and genomic technology to develop new drugs intended to cure genetic diseases. |  |  | Dec 30, 2024 |  |
| Reforgene Medicine | Reforgene Medicine is a biomedical company that uses gene editing and genomic technology to develop new drugs intended to cure genetic diseases. | $15M | Series B | Apr 28, 2023 |  |
| PackGene Biotech | PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, wedeliver cost-effective, dependable, and scalable production solutions. |  | Series C | Apr 18, 2023 |  |
| Asieris Pharmaceuticals | Asieris Pharmaceuticals is a Chinese biotech company focusing on therapeutic areas in oncology and multidrug-resistant infections. | $105.6M | Series D | Nov 11, 2020 |  |

6 of 6 investments shown.

## Co-investors
- [Guangzhou Guoju Venture Capital](https://shizune.co/investors/profile/guangzhou-guoju-venture-capital) — VC Fund, 2 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 2 deals together
- [Xinxing Fund](https://shizune.co/investors/profile/xinxing-fund) — VC Fund, 2 deals together
- [Alwin Capital](https://shizune.co/investors/profile/alwin-capital) — VC Fund, 1 deal together
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 1 deal together
- [BioVenture](https://shizune.co/investors/profile/bioventure) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does IFSC invest in?

IFSC invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did IFSC last invest?

The most recent investment recorded for IFSC closed in Jul 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co